Information Provided By:
Fly News Breaks for July 20, 2018
VKTX
Jul 20, 2018 | 07:07 EDT
SunTrust analyst Edward Nash initiated Viking Therapeutics with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non- alcoholic steatohepatitis disease, or NASH. The analyst adds that VK2809 demonstrated a significant reduction in multiple lipid parameters in phase 1b trials, and also notes that the stock is trading at a significant discount relative to other companies targeting NASH.
News For VKTX From the Last 2 Days
There are no results for your query VKTX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.